Complementary mechanisms of angiotensin receptor blockers and calcium channel blockers in managing hypertension

Postgraduate Medicine

Volumn 121, Issue 2, 2009, Pages 40-48

  Neutel, Joel M ^a  

^a Orange County Research Center   (United States)

Author keywords

Amlodipine besylate; Angiotensin receptor blockers; Calcium channel blockers; Hypertension; Olmesartan medoxomil

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS OLMESARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN POTASSIUM; OLMESARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; COUGHING; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; HYPOKALEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; DRUG COMBINATION; REVIEW;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CALCIUM CHANNEL BLOCKERS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; IMIDAZOLES; TETRAZOLES;

EID: 64849115526     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.03.1975     Document Type: Article

References (50)

1. Chobanian AV, Bakris GL, Black HR, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.
2. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462-1536.
3. Whitworth JA; World Health Organization. International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983-1992.
4. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427. (Pubitemid 36776153)
5. Smith DH. Fixed-dose combination antihypertensives and reduction in target organ damage: are they all the same? Am J Cardiovasc Drugs. 2007;7(6):413-422. (Pubitemid 350256049)
6. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-719. (Pubitemid 47176510)
7. Padilla MC, Armas-Hernández MJ, Hernández RH, Israili ZH, Valasco M. Update of diuretics in the treatment of hypertension. Am J Ther. 2007;14(2):154-160. (Pubitemid 46597653)
8. Dahlof B, Sever PS, Poulter NR, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. (Pubitemid 41265663)
9. Mason JM, Dickinson HO, Nicolson DJ, Campbell F, Ford GA, Williams B. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens. 2005;23(10):1777-1781. (Pubitemid 41830411)
10. Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007(1):CD002003.
11. Beevers DG. The end of beta blockers for uncomplicated hypertension? Lancet. 2005;366(9496):1510-1512. (Pubitemid 41540100)
12. Norris K, Neutel JM. Emerging insights in the first-step use of antihypertensive combination therapy. J Clin Hypertens (Greenwich). 2007;9(12 suppl 5):5-14.
13. White WB. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension. Blood Press Monit. 2008;13(2):123-129.
14. Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004;17(3):252-259. (Pubitemid 38293331)
15. Haller H. Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk. Int J Clin Pract. 2008;62(5):781-790.
16. Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol. 2005;42(suppl 1):S17-S25. (Pubitemid 43309187)
17. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab. 2004;30(6):487-496. (Pubitemid 40070350)
18. Aguilar D, Solomon SD. ACE inhibitors and angiotensin receptor antagonists and the incidence of new-onset diabetes mellitus: an emerging theme. Drugs. 2006;66(9):1169-1177. (Pubitemid 44055871)
19. Guazzi MD, De Cesare N, Galli C, et al. Calcium-channel blockade with nifedipine and angiotensin converting-enzyme inhibition with captopril in the therapy of patients with severe primary hypertension. Circulation. 1984;70(2):279-284. (Pubitemid 14053050)
20. Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428.
21. Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich). 2008;10(1 suppl 1):27-32.
22. Plosker GL, Robinson DM. Amlodipine/valsartan: fixed-dose combination in hypertension. Drugs. 2008;68(3):373-381.
23. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29(4):563-580. (Pubitemid 47028551)
24. Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30(4):587-604.
25. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. (Pubitemid 34286536)
26. Julius S, Kjeldsen SE, Weber M, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-2031. (Pubitemid 38781102)
27. Goodfriend TL. Angiotensins: actions and receptors. In: Izzo JL Jr, Black HR, Goodfriend TL, eds. Hypertension Primer: The Essentials of High Blood Pressure. 3rd ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2003;8-11.
28. Mire DE, Silfani TN, Pugsley MK. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol. 2005;46(5):585-593. (Pubitemid 41527750)
29. Weber MA. Angiotensin II receptor blockers. In: Izzo JL Jr, Black HR, Goodfriend TL, eds. Hypertension Primer: The Essentials of High Blood Pressure. 3rd ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2003;430-432.
30. Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension. 2000;35(1 pt 2):155-163. (Pubitemid 30054167)
31. Weir MR, Izzo JL Jr. Calcium antagonists. In: Izzo JL Jr, Black HR, Goodfriend TL, eds. Hypertension Primer, The Essentials of High Blood Pressure. 3rd ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2003;433-437.
32. Basile J. The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens (Greenwich). 2004;6(11):621-629.
33. Mizuno Y, Jacob RF, Mason RP. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease. Am J Hypertens. 2008;21(10):1076-1085.
34. Siragy HM, Xue C, Webb RL. Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-alpha production after cardiac ischemia. J Cardiovasc Pharmacol. 2006;47(5):636-642. (Pubitemid 44309655)
35. Neutel JM, Smith DH, Weber MA, Schofield L, Purkayastha D, Gatlin M. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. J Clin Hypertens (Greenwich). 2005;7(11):641-646.
36. Morgan T, Anderson A. A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension. Am J Hypertens. 2002;15(6):544-549. (Pubitemid 34596962)
37. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(suppl 1):169S-173S. (Pubitemid 43265218)
38. Kohlmann O Jr, Oigman W, Mion D Jr, et al. [The "LOTHAR" study: evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertension]. Arq Bras Cardiol. 2006;86(1):39-51.
39. Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, et al. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens. 2008;21(1):61-66.
40. Kereiakes DJ, Neutel JM, Punzi HA, Xu J, Lipka LJ, Dubiel R. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs. 2007;7(5):361-372. (Pubitemid 47624540)
41. Minami J, Ishimitsu T, Matsuoka H. Pretreatment plasma renin activity levels correlate with the blood pressure response to telmisartan in essential hypertension. Am J Hypertens. 2008;21(1):10-13.
42. Neutel JM, Smith DH, Silfani TN, Lee Y, Weber MA. Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. J Hum Hypertens. 2006;20(4):255-262.
43. Destro M, Luckow A, Samson M, Kandra A, Brunel P. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized double-blind, multicenter study: the EX-EFFeCTS Study. J Am Soc Hypertens. 2008;2(4):294-302.
44. Schrader J, Salvetti A, Calvo C, et al. The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. Int J Clin Pract. 2009;63(2):217-225.
45. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3(5):283-291, 318. (Pubitemid 33040384)
46. Oparil S, Silfani TN, Walker JF. Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens. 2005;18(2 pt 1):287-294. (Pubitemid 40332560)
47. Giles TD, Oparil S, Silfani TN, Wang A, Walker JF. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007;9(3):187-195.
48. Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs. 2008;68(9):1207-1225.
49. Krum H. Critical assessment of calcium antagonists. Aust Fam Physician. 1997;26(7):841-845, 847-848.
50. Ofili EO. Dispelling the myth of "aggressive" antihypertensive therapy. J Clin Hypertens (Greenwich). 2006;8(1 suppl 1):4-11.